


Corporate Governance

202	Group Structure and Shareholders
204	Capital Structure
206	Board of Directors
216	Executive Committee
222	Compensation, Shareholdings and Loans
222	Shareholders Participation Rights
223	Changes of Control and Defense Measures
224	Auditors
225	Information Policy and Key Reporting Dates


Group Structure and Shareholders

Lonza Board of Directors



The Chairperson of the Board of Directors takes responsibility for all sustainability related issues

Lonza Executive Committee (EC)



Lonza²



¹ Rodolfo J. Savitzky was Chief Financial Officer until November 2021

² The former Specialty Ingredients business was sold effective 1 July 2021

Operational Group Structure

Divisions

In 2021, Lonza's activities were organized in the following four divisions¹:

- Biologics
- Small Molecules
- Cell & Gene
- Capsules & Health Ingredients

Corporate and Business Functions

Corporate and Business Functions include Legal, Communications, Investor Relations, Environment, Health and Safety (EHS), Sustainability, Human Resources, Finance, Commercial and Marketing, Quality, and Operations.

Global Business Services Organization

Our Global Business Services Organization (GBSO) supports our divisions, operational units and corporate functions with transactional services in finance and HR. The GBSO focuses on standardization and automation of processes to drive productivity and higher quality services. Service delivery through the GBSO is centralized in Manchester (UK) to support EMEA markets and in San José (CR) for the Americas.

Holding Company and Listed Companies

Lonza Group Ltd, with our registered office in Basel (CH), is the ultimate parent company of the Lonza Group. With the exception of Lonza Group Ltd, no equity securities of a company controlled by Lonza Group are listed. Please refer to the Shares and Participation Certificates section, [page 205](#), for information on the listed shares, the stock exchanges on which Lonza Group Ltd is listed and the market capitalization.

Principal Subsidiaries and Joint Ventures

The principal subsidiaries and joint ventures of the Lonza Group are shown in note 33, Principal Subsidiaries and Joint Ventures, [page 150](#).

Significant Shareholders

According to disclosure notifications filed with Lonza, the following shareholders held more than 3% of the Lonza share capital as of 31 December 2021:

BlackRock, Inc., New York, NY (USA) 9.00%.

The current significant shareholders as well as further disclosure notifications registered in 2021 can be found at the [SIX Swiss Exchange disclosure platform](#).

Cross-Shareholdings

Lonza Group Ltd has not entered into any cross-shareholdings.

¹ The former Specialty Ingredients business was sold effective 1 July 2021

Capital Structure

Share Capital

As of 31 December 2021, Lonza's share capital amounted to CHF 74,468,752 fully paid-in and divided into 74,468,752 registered shares with a par value of CHF 1 each.

Shareholder Structure

	31.12.2021		31.12.2020	
	Shareholders in %	Shares in %	Shareholders in %	Shares in %
Switzerland	91.08	17.86	90.75	17.88
United Kingdom	0.40	16.99	0.45	20.16
USA	0.98	11.53	1.30	10.81
Others	7.54	6.38	7.50	7.22
Shares in transit		46.86		43.68
Treasury shares without voting rights		0.38		0.25
Total	100	100	100	100
Total number of shares		74,468,752		74,468,752

Share Register

	31.12.2021	31.12.2020
Registered shareholders	32,520	26,510
Registered shares with voting rights	31,175,762	31,542,413
Share distribution:		
1 - 100	23,562	17,825
101 - 1,000	7,758	7,471
1,001 - 10,000	951	971
10,001 - 100,000	202	192
100,001 - 1,000,000	41	46
Over 1,000,000	6	5
Total registered shareholders	32,520	26,510

Authorized and Conditional Capital

The Board of Directors is authorized to increase, at any time until 6 May 2023, the share capital of Lonza through the issuance of a maximum of 7,500,000 fully paid-in registered shares with a par value of CHF 1 each up to a maximum aggregate amount of CHF 7,500,000. This authorized capital was created by the Annual General Meeting held on 6 May 2021. The additional terms and conditions of the authorized capital (including the group of beneficiaries who have the right to subscribe for this additional capital) are set out in Article 4^{ter} of the [Lonza Articles of Association](#).

Conditional Capital: Lonza's share capital may be increased through the issuance of a maximum of 7,500,000 fully paid-in registered shares with a par value of CHF 1 each up to a maximum aggregate amount of CHF 7,500,000. This conditional capital was created by the Annual General Meeting on 25 April 2017. The additional terms and conditions of the conditional capital (including the group of beneficiaries who have the right to subscribe for this additional capital) are set out in Article 4^{bis} of the [Lonza Articles of Association](#).

According to Article 4^{quater} of the [Lonza Articles of Association](#), the capital increases in the form of conditional capital and authorized capital may increase Lonza's share capital only by a maximum aggregate amount of CHF 7,500,000, which equates to ≈10% of the existing share capital.

Changes in Capital

	2021	2020	2019	2018
Share capital in CHF	74,468,752	74,468,752	74,468,752	74,468,752
Registered shares	74,468,752	74,468,752	74,468,752	74,468,752
Par value in CHF / share	1	1	1	1

Shares and Participation Certificates

Lonza registered shares, with a par value of CHF 1 each, are listed on the SIX Swiss Exchange (SIX), with secondary listing on the SGX Singapore Exchange. In Switzerland, they have been included in the Swiss Market Index (SMI) since 3 May 2017.

Lonza has not issued any participation certificates ("Partizipationscheine", non-voting shares).

Stock Exchange Listing / Trading:

SIX Swiss Exchange
SGX Singapore Exchange

Common Stock Symbols:

Bloomberg LONN SW
Reuters LONN.S
Six Swiss Exchange LONN
SGX Singapore Exchange O6Z

Security Number:

Valor 001384101
ISIN CH0013841017

On 31 December 2021, Lonza had a market capitalization of CHF 56,715 million (2020: CHF 42,357 million).

Profit-Sharing Certificates

Lonza has not issued any non-voting equity security ("Genussscheine", profit-sharing certificates).

Limitations on Transferability and Nominee Registrations

Purchasers of registered shares declaring that they have acquired these shares in their own name and for their own account will be entered without limitation as shareholders with voting rights in the share register. Persons who do not declare to have acquired the respective shares in their own name and for their own account are considered "nominees" and will be entered with voting rights in the share register up to a maximum of 2% of the share capital, unless the actually entitled persons are revealed. The details are set out in Article 6 of the [Lonza Articles of Association](#). This "nominee" exemption allows for non-registration up to 2% of the share capital. It is not meant to serve as takeover defense. This restriction may only be removed by a resolution of the Shareholders' Meeting with a quorum in accordance with Swiss law.

Convertible Bonds

Neither Lonza Group Ltd nor any of its subsidiaries has outstanding convertible bonds.

Options

As of 31 December 2021, no options or warrants to acquire shares issued by or on behalf of Lonza Group Ltd were outstanding.

Board of Directors

The Board of Directors is currently made up of 8 members.

Name	Nationality	Year of birth	Year of initial appointment	Expiration of current term in office	Independence
Albert M. Baehny	Swiss	1952	2017	2022	Independent
Werner Bauer	Swiss	1950	2013	2022	Independent
Dorothee Deuring	Austrian	1968	2020	2022	Independent
Angelica Kohlmann	German-Brazilian	1960	2018	2022	Independent
Christoph Mäder	Swiss	1959	2016	2022	Independent
Barbara Richmond	British	1960	2014	2022	Independent
Jürgen Steinemann	German	1958	2014	2022	Independent
Olivier Verscheure	Belgian	1972	2018	2022	Independent

Limitation of Number of Mandates

According to Article 26 of [Lonza's Articles of Association](#), no member of the Board of Directors may hold more than:

- Eight additional mandates in listed and non-listed companies, out of which not more than four mandates may be in listed companies
- Ten mandates in associations, charitable foundations, trusts and employee welfare foundations.

The Chairperson of the Board of Directors may not hold more than eight additional mandates in listed and non-listed companies, out of which no more than three may be in listed companies.

Mandates are mandates in the supreme governing body of a legal entity that is required to be registered in the commercial register or a comparable foreign register. Mandates in different legal entities that are under joint control or in the same beneficial ownership are deemed to be a single mandate. Mandates in companies that are controlled by Lonza or that control Lonza are not subject to the limitation set forth above. No member of the Board of Directors may hold more than five mandates at the request of Lonza or companies controlled by it.

All Board members comply with the provisions regarding their mandates. This is verified by Lonza on a regular basis.

Elections and Terms of Office

Each member of the Board of Directors is individually elected by the Annual General Meeting for a term of office of one year until the end of the next Annual General Meeting. Board members may not serve more than nine complete terms of office on the Board of Directors. If deemed in the best interest of the Company, the Board of Directors can extend this limit. The Chairperson of the Board of Directors is elected by the Shareholders' Meeting. The Vice-Chairperson is appointed by the Board of Directors. The members of the Nomination and Compensation Committee are elected by the Shareholders' Meeting on an annual basis. The members of the other Board Committees are appointed by the Board of Directors. The Chairpersons of the Board Committees are nominated by the members of the respective Board Committees, except the Chairperson of the Nomination and Compensation Committee that is elected by the Board of Directors in corpore.

Internal Organizational Structure

The Board of Directors consists of the Chairperson, the Vice-Chairperson and the other Board members. In accordance with

[Lonza's Articles of Association](#), the number of members must be at least five. The members of the Board of Directors sat on the following committees in 2021:

Name	Audit and Compliance Committee	Nomination and Compensation Committee	Innovation and Technology Committee
Albert M. Baehny			Member
Werner Bauer			Chairman
Dorothee Deuring	Chairperson		
Angelica Kohlmann		Member	Member
Christoph Mäder	Member	Chairman	
Barbara Richmond	Member		
Jürgen Steinemann		Member	
Olivier Verscheure			Member

The Board of Directors strives to select the committee members based on their professional background and experience.

Audit and Compliance Committee

The Audit and Compliance Committee meets and consults regularly with the Executive Committee, Lonza Audit Services and the independent external auditors to review the scope and results of their work and their performance, according to the Audit and Compliance Committee Charter.

Among other responsibilities, the Audit and Compliance Committee reviews (i) the external auditors' independence, (ii) the systems of internal control and financial reporting, (iii) the risk management system, (iv) compliance with laws, regulations and policies and (v) Lonza's financial statements and results (including releases). The Audit and Compliance Committee is empowered to decide the tasks assigned to it and regularly informs the full Board of Directors on all matters discussed and decided in its meetings. The members of the ACC benefit from their broad professional backgrounds and experience as finance director and member of other audit committees, Chief Financial Officer (CFO) and Group General Counsel for their committee work. Internal and external auditors have full and free access to the Audit and Compliance Committee. The Lonza Audit Services are overseen by the Audit and Compliance Committee and have a direct reporting line to the Chairperson of the Audit and Compliance Committee.

Nomination and Compensation Committee

The Nomination and Compensation Committee is entrusted with responsibilities that include the review and recommendation of compensation policies and plans (e.g. incentive compensation and equity plans) and the compensation of the members of the Executive Committee. This committee also makes an assessment to ensure that the area of nomination and compensation is in compliance with the standards set forth in the associated charter. In addition, the Nomination and Compensation Committee evaluates potential members of the Board of Directors. The Nomination and Compensation Committee is empowered to decide the tasks assigned to it and regularly informs the full Board of Directors on matters discussed in its meetings and submits proposals for Board decision in accordance with the Nomination and Compensation Committee Charter.

Innovation and Technology Committee

The Innovation and Technology Committee monitors potential technology breakthroughs, supports management in driving innovation projects and provides and facilitates contacts, e.g. with academia and research institutions. With regard to the tasks assigned to it, the Innovation and Technology Committee regularly informs the full Board of Directors on all matters discussed and decided in its meetings, in accordance with the Innovation and Technology Committee Charter.

Number of Meetings, Duration and Attendance

Name	Board of Directors	Audit and Compliance Committee	Nomination and Compensation Committee	Innovation and Technology Committee
Number of meetings	9	5	7	5
Average duration	5h	3h	2.5h	2h
Overall attendance	96%	100%	100%	100%

[The Regulations Governing Internal Organization and Board Committees](#) set out in detail the powers and responsibilities of the Board of Directors, its Committees and the Executive Committee. The Board Committees provide support to the Board of Directors in their respective areas of responsibility. The Board of Directors meets with all members of the Executive Committee at each ordinary Board meeting for business updates and decisions to be taken. The Chief Executive Officer (CEO) is a permanent guest of

the Innovation and Technology Committee and is regularly invited to the meetings of the Nomination and Compensation Committee. The Chief Financial Officer (CFO) attends all meetings of the Audit and Compliance Committee. The Chief Human Resources Officer (CHRO) is regularly invited to the meetings of the Nomination and Compensation Committee.

Attendance

Name	Board of Directors	Audit and Compliance Committee	Nomination and Compensation Committee	Innovation and Technology Committee
Meeting Total	9	5	7	5
Albert M. Baehny	9			5
Werner Bauer	8			5
Dorothee Deuring	9	5		
Angelica Kohlmann	9		7	5
Christoph Mäder	8	3 ¹	7	
Barbara Richmond	9	5		
Jürgen Steinemann	8	2 ²	7	
Olivier Verscheure	9			5

¹ Christoph Mäder became member of the ACC after the Annual General Meeting held on 6 May 2021 and attended all ACC meetings after his appointment

² Jürgen Steinemann was member of the ACC until the Annual General Meeting held on 6 May 2021 and attended all ACC meetings during his term of office

Areas of Responsibility

In accordance with the law and the [Lonza Articles of Association](#), the Board of Directors is the supreme governance body of the Group. The Board of Directors is responsible for the tasks assigned to it according to (i) Article 18 of the Lonza Articles of Association and (ii) [the Regulations Governing Internal Organization and Board Committees](#) (Article 2.8). The Board of Directors defines the strategic direction and is responsible for the ultimate management of Lonza as well as the supervision of the persons entrusted with Group management. It is responsible for issuing the necessary instructions especially with regard to compliance with the law, the Articles of Association and the regulations and directives. In compliance with the law and the Articles of Association, the Board of Directors has – with the exception of non-delegable and inalienable duties – delegated the management of the company to the Executive Committee (EC). The Board of Directors commits itself to maintaining the highest standards of integrity and transparency in its governance of Lonza. On an annual basis, the Board undertakes a self-assessment process. The aim is to achieve continuous improvement in the functioning of the Board.

Governance and oversight over Sustainability and environmental, social and governance (ESG) is with the Board of Directors, headed by the Chairperson of the Board, with specific aspects to be covered by the Board's Committees (Nomination and Compensation Committee, Audit and Compliance Committee, and Innovation and Technology Committee). While the Board acts as sponsor and overall owner of the program, the implementation is the responsibility of the EC. The Board and its Committees review and endorse Lonza's sustainability efforts and reporting. Sustainability includes ESG topics of importance relating to Lonza's business and stakeholders. The Sustainability and Risk Committee (SRC), headed by the Lonza Group General Counsel and Company Secretary, manages identified material topics (as shown in the Materiality Matrix in the 2021 [Sustainability Report](#)) and is responsible for sustainability reporting. The Head of Global Sustainability and the Head of Global Environment, Health and

Safety (EHS) and their teams are responsible for proposing the corporate sustainability strategy and for implementation and oversight of the Safety and Sustainability Policy. The Global Sustainability and EHS teams report to Lonza's Group General Counsel.

In 2021, as Lonza started a new chapter as a strategic partner to the healthcare industry, we created a dedicated Sustainability Group to further advance the company's sustainability agenda and its internal and external sustainability profile. The former Sustainability Council was replaced by the Sustainability and Risk Committee (SRC) and the Safety and Sustainability Steering Board (SSSB) which includes operations and supply chain functions.

Information and Control Instruments

The Board of Directors ensures that it receives sufficient information from the Executive Committee to perform its supervisory duty and to make the decisions that are reserved for the Board of Directors through several means discussed below.

Board Information

[The Regulations Governing Internal Organization and Board Committees](#) require the CEO to ensure that the Executive Committee is informed about business activities of the Group and together with the Chairperson – inform the Board of Directors on the business activities of the Group and keep the Board of Directors constantly informed on all important business transactions and issues. In addition, during Board meetings, each member of the Board may request information from the other members of the Board, as well as from the members of the Executive Committee present on all affairs of the Company and the Group. Outside of Board meetings, each member of the Board may request from the members of the Executive Committee information concerning the course of business of the Company and the Group.

Regular Reports to the Board

In addition to the documents required to pass resolutions, the Board of Directors receives the following reports:

- Reports on the sales and earnings performance of the Group structured by divisions
- Reports on the cash flows, debt and debt-equity ratio, plus other relevant key figures for the Group on a quarterly basis
- Qualitative assessments of the divisions on a quarterly basis
- Reports of the external audit for the Full-Year Results and procedures performed on the Half-Year Results (through the Audit and Compliance Committee)
- In cases involving extraordinary events of considerable commercial relevance, the Board of Directors receives direct, immediate information
- Risk assessment reports submitted at least once per year; they are designed to provide the Board with a consistent, Group-wide perspective of key risks.

Internal Audit

The Board of Directors, through the Audit and Compliance Committee, is supported by Lonza Audit Services. The team of nine authorized internal audit positions reviews financial, operational and information technology related activities of the entire Lonza Group with a risk-based audit program. The audit teams continually evaluate the adequacy and effectiveness of the system of internal controls as well as compliance with company policies, procedures, and external regulations, and they recommend appropriate actions to correct deficiencies identified. In 2021, Lonza Audit Services delivered 15 internal audit reports to the Audit and Compliance Committee, and they also informed the Committee about the status of implementation of agreed action plans with seven follow-up audit reports. In the second year of the COVID-19 pandemic and associated travel restrictions performing audits remotely continued to be the norm. With significantly improved remote audit processes and tools, the quality of offsite audits is now similar to onsite reviews.

Internal Control System

Lonza has implemented a financial control framework, in accordance with the requirements of the Swiss law, comprising relevant policies, procedures and controls. It provides the Group's management and Board of Directors a reasonable degree of assurance that business processes are performed efficiently and effectively, in compliance with policies and laws, assets are safeguarded and financial statements are reliable.

Compliance Instruments

In addition to the above-mentioned control instruments, Lonza has implemented various other measures to improve compliance within the Group. The implementation of these measures is supervised by the Audit and Compliance Committee. One of these measures is the issuance of a [Code of Conduct](#) that expresses Lonza's core principles and values in regard to professional business behavior and provides assistance in recognizing, understanding and complying with the laws and ethical standards that govern Lonza's business activities. The Code of Conduct is available to all employees and information about it has been widely circulated within the Group. Lonza employees have to pass iComply tests in online training courses, dealing with topics such as those addressed by the Code of Conduct, in particular antibribery, competition law and conflicts of interest. In addition to these measures, Lonza offers a "whistleblower" hotline (known as "Lonza Ethics Hotline"), which is operated by an external company. Cases disclosed through the "whistleblower" hotline are ultimately reported to the Audit and Compliance Committee. Lonza periodically reviews and updates its policies to address changes in laws and regulations and strengthen compliance.

Risk Assessment

The Board of Directors carries out risk assessments on a minimum of an annual basis. The objective of the risk assessments is to make the principal risks to which Lonza is exposed more transparent and to improve risk mitigation. In its risk assessment for 2021, the Board of Directors identified inter alia commercial, operational and cybersecurity risks for which corresponding risk mitigation measures have been adopted.



CVs Board of Directors

Members of the Board of Directors as of 31 December 2021



Albert M. Baehny

Nationality: Swiss
Year of birth: 1952

Chairman of the Board of Directors of Lonza Group Ltd (since 2018), Independent member of the Board of Directors of Lonza Group Ltd (since April 2017).

Albert M. Baehny holds a degree in biology from the University of Fribourg (CH).

Current Activities and Functions

Public Company Boards

- Member of the Board of Directors of Investis Group Holding SA (since 2016)
- Chairman of the Board of Directors of Geberit AG (since 2011)

Former Activities and Functions

- CEO ad interim of Lonza Group Ltd (2019–2020)
- CEO of Geberit Group (2005–2014)
- Head of Group Division Marketing and Sales Europe for Geberit Group (2003–2004)
- Senior Vice-President at Wacker Chemie AG (2001–2002)
- Various Marketing, Sales, Strategic Planning and Global Management Positions with:
 - Vantico (2000–2001)
 - Ciba-Geigy / Ciba Specialty Chemicals (1994–2000)
 - Dow Chemicals Europe (1981–1993)
 - Serono-Hypolab (1979–1981)



Christoph Mäder

Nationality: Swiss
Year of birth: 1959

Vice-Chairman (since April 2020) and Lead Independent Director (since November 2019) of the Board of Directors of Lonza Group Ltd (since April 2020); Independent member of the Board of Directors of Lonza Group Ltd (since April 2016).

Christoph Mäder holds a Master's degree in law from the University of Basel (CH) and is admitted to the Swiss Bar.

Current Activities and Functions

Public Company Boards

- Member of the Board of Directors EMS Chemie Holding AG (since 2018)
- Member of the Board of Directors Baloise Holding AG (since 2019)

Further Appointments

- President of Economiesuisse (since 2020)
- Member of the Board of Directors Assivalor AG (since 2019)
- Member of the Advisory Board of Accenture Switzerland (since 2019)
- Partner at the law firm Becker-Gurini-Hanhart-Vogt (since 2019)
- Member of the Council of Schweizer Jugend forscht (since 2018)
- Member of the Advisory Board of Vereinigung Schweizerischer Unternehmen in Deutschland (since 2016)
- Member of the Advisory Board of Loeba GmbH (since 2014)

Former Activities and Functions

- Group General Counsel (including oversight of the risk and compliance function) and Member of the Group Executive Committee of Syngenta (2000–2018)
- Member of the Board Committee of economiesuisse (2008–2019)
- Vice-Chairman of economiesuisse (2011–2017)
- Member of the Executive Board of the Business and Industry Advisory Committee (BIAC) for the Organization for Economic Co-operation and Development (OECD) (2012–2016)
- Member of the Board of scienceindustries (2006–2018)
- Member of the Board of the Basel Chamber of Commerce (2002–2018)
- Head of Legal & Public Affairs for Novartis Crop Protection AG (1999–2000)
- Senior Corporate Counsel for Novartis International AG (1992–1998)



Werner Bauer

Nationality: Swiss
Year of birth: 1950

Independent member of the Board of Directors of Lonza Group Ltd (since April 2013).

Werner Bauer holds a diploma and PhD in chemical engineering from the University of Erlangen-Nürnberg (DE). He has received several scientific honors, among others the BioAlps Award 2011 and Honorary Senator from the Technical University of Munich (DE).

Current Activities and Functions

Public Company Boards

- Member of the Board of Directors of SIG Combibloc Group AG (since 2018)
- Vice-Chairman of the Board of Directors of Givaudan SA (since 2014)

Further Appointments

- Member of the Board of Directors of the Urs Bühler Innovation Fund (since 2019)
- Vice-Chairman of the Supervisory Board of Bertelsmann SE & Co. KGaA (since 2012)
- Chairman of the Board of Trustees of the Bertelsmann Foundation (since 2003)

Former Activities and Functions

- Member of the Supervisory Board of GEA Group AG (2011–2018)
- Chairman of the Supervisory Board of Nestlé Deutschland AG (2007–2017)
- Executive Vice-President of Nestlé S.A., Head of Innovation, Technology, Research and Development (2007–2013)
- Executive Vice-President of Nestlé S.A., Head of Technical, Production, Environment, Research & Development (2002–2007)
- Various managerial positions of increasing responsibility at Nestlé (1990–2002)
- Chairman of the Board of Directors of Galderma Pharma S.A. (2011–2014)
- Member of the Board of Directors of L'ORÉAL, France (2005–2012)
- Member of the Board of Directors of Alcon Inc., Switzerland (2002–2010)
- Director of the Fraunhofer Institute for Food Technology & Packaging and Professor in Bioprocess Technology at Technical University Munich (DE) (1985–1990)
- Professor of Chemical Engineering at the Technical University of Hamburg (DE) (1980–1985)



Dorothee Deuring

Nationality: Austrian
Year of birth: 1968

Independent member of the Board of Directors of Lonza Group Ltd (since April 2020).

Non-Executive Director and Corporate Finance Adviser, who brings more than 25 years of experience in the fields of manufacturing, biotech, pharmaceuticals and banking. Ms Deuring currently serves on the board of several companies including Axpo, Bilfinger and Elementis. Her Board memberships span the energy, plant engineering, chemical and biopharmaceutical sectors. She received her Master of Science in Chemistry from Université Louis Pasteur, Strasbourg in 1994. In 1996 she received her Master in Business Administration from INSEAD, Fontainebleau (FR).

Current Activities and Functions

Public Company Boards

- Supervisory Board Member, Immofinanz AG (since 2021)
- Member of the Board of Directors, Member of the Audit Committee of Axpo Holding AG (since 2017)
- Member of the Board of Directors, Member of the Audit and Remuneration Committees of Elementis PLC (since 2017)

Activity

- Independent Corporate Finance Adviser (since 2014)

Former Activities and Functions

- Supervisory Board Member, Member of the Audit Committee of Bilfinger SE (2016–2021)
- Member of the Board of Directors of PIQUR Therapeutics AG (2019–2021)
- Member of the Board of Directors of Selecta AG (2020)
- Supervisory Board Member (Beirat) of Röchling Group SE & Co. KG (2016–2019)
- Head of Corporate Advisory Group Europe, Managing Director Wealth Management Division of UBS AG (2011–2014)
- Managing Director Investment Banking, Head Healthcare and Chemicals M&A of Bankhaus Sal. Oppenheim Jr & Cie (2007–2009)
- Vice Director, Corporate Finance, Mergers & Acquisitions; Vice Director, Diagnostics Division, Business Development for F. Hoffman-La Roche AG (2003–2007)
- Founder, Owner Manager and Board Member of CoCap AG (1998–2003)
- Consultant of McKinsey & Company (1997–1998)
- Managing Director of K. Deuring & Co (1993–1997)



Angelica Kohlmann

Nationality: German-Brazilian
Year of birth: 1960

Independent member of the Board of Directors of Lonza Group Ltd (since May 2018).

Angelica Kohlmann holds a MD and doctorate in medicine from Hamburg University (DE).

Current Activities and Functions

- Member International Advisory Board IE University and Business School, Madrid (since 2017)
- Chairperson Board of Directors, Bloom Diagnostics AG (since 2014)
- Chairperson Board of Directors, Kohlmann & Co AG (since 2013)
- International investor in biotech and tech, based in Switzerland (since 2014)
- Board Observer Teralytics AG (since 2017)
- Chairperson of the Advisory Board Peter Drucker Society Europe / Global Peter Drucker Forum, Vienna (since 2009)

Former Activities and Functions

- Member Advisory Board UBS Unique (2017–2018)
- Director Trinnacle Fund Ltd (2016–2017)
- Member Board of Directors Teralytics AG (2013–2016)
- Founder & CEO Ifitech GmbH, Germany (2010–2017)
- International investor in biotech and tech, based in Germany (2000–2013)
- International consultant for strategy, management, investments and restructuring (1992–1999)
- Head global restructuring Behringwerke AG, Germany (1990–1992)
- Member Board Staff Hoechst AG, Germany (1988–1990)
- International Marketing Group Leader at Behringwerke AG (1986–1988)
- MD Anderson Cancer Center, Houston and Memorial Sloan Kettering Cancer Center, New York, USA – various cancer research functions



Barbara Richmond

Nationality: British
Year of birth: 1960

Independent member of the Board of Directors of Lonza Group Ltd (since April 2014).

Barbara Richmond holds a first-class degree in management science from the University of Manchester Institute of Science and Technology in England. Barbara Richmond has substantial knowledge as a financial expert, demonstrated by her roles as Chief Financial Officer for various companies. She is a Fellow of the Institute of Chartered Accountants in England and Wales.

Current Activities and Functions

- Group CFO of Redrow plc (since 2010)

Former Activities and Functions

- Group CFO (including oversight of the accounting function) of Inchcape plc (2006–2009)
- Non-Executive Director and Audit Committee Chair of Scarborough Building Society until its merger with The Skipton Building Society (2005–2009)
- Non-Executive Director, Senior Independent Director and Audit Committee Chair of Carclo Group plc (2000–2006)
- Group CFO of Croda International plc (1997–2006) with dual role as Group CFO and President of Active Ingredients and Industrial Chemicals from 2002 to 2006
- Group CFO of Whessoe plc in 1993 (1993–1997)
- Various financial roles in Alstom Group SA (1987–1992)
- Auditor and management consultant for Arthur Andersen (1981–1984)



Jürgen Steinemann

Nationality: German
Year of birth: 1958

Independent member of the Board of Directors of Lonza Group Ltd (since April 2014). Jürgen Steinemann holds a degree in Economics and Business Management from the European Business School in Wiesbaden (DE), London (UK) and Paris (FR).

Current Activities and Functions

Public Company Boards

- Chairman of the Supervisory Board of Metro AG (since 2015)

Further Appointments

- Investor in food and agro businesses
- Managing Director of JBS Holding GmbH (since 2017)
- Chairman of the Supervisory Board of Bankiva B.V. (since 2017)
- Member of the Advisory Board of Tower Brook Capital Partners LP (since 2017)
- Member of the Supervisory Board of Big Dutchman AG (since 2015)

Former Activities and Functions

- Member of the Board of Directors of Barry Callebaut AG (2015–2020)
- Chief Executive Officer of Barry Callebaut Ltd (2009–2015)
- Member of the Board of the Swiss-American Chamber of Commerce (2011–2015)
- Member of the Executive Board and Chief Operating Officer of Nutreco (2001–2009)
- Chief Executive Officer of Lodders Croklaan (1999–2001)
- Various senior positions in business-to-business marketing and sales with the former Eridania Béghin-Say Group, ultimately in the "Corporate Plan et Stratégie" unit at the head office in Paris (1990–1998)



Olivier Verscheure

Nationality: Belgian
Year of birth: 1972

Independent member of the Board of Directors of Lonza Group Ltd (since May 2018).

Olivier Verscheure holds a PhD in computer science from the Swiss Federal Institute of Technology, Lausanne (CH) (EPFL, July 1999).

Current Activities and Functions

- Expert in the Strategy Working Group on Data, Computing and Digital Research Infrastructures in the State Secretariat for Education, Research and Innovation (SERI) (since 2019)
- Member of the Foundation Council of SWITCH (since 2019)
- Founder and Executive Director of the Swiss Data Science Center, a joint venture between EPFL and ETH Zürich (since 2016)
- Member of the Executive Committee of Personalized Health and Related Technologies (PHRT), an ETH Domain Strategic Focus Area (since 2017)
- Co-academic Director, Certificate of Advanced Studies (CAS), Data Science and Management, HEC Lausanne and EPFL (since 2018)

Former Activities and Functions

- Lab Program Director and Senior Research Manager at IBM Research Ireland (2010–2016)
- Research Manager and Senior Member of the Research Staff at the IBM T.J. Watson Research Center (1999–2010)

Executive Committee

The members of the Executive Committee are appointed by the Board of Directors. Lonza's Executive Committee performs the duties assigned to it by the Board of Directors under the terms of the [Regulations Governing Internal Organization and Board Committees](#). It is responsible for managing Lonza worldwide and for implementing policies and strategies as defined by the Board

of Directors. The Executive Committee supports and coordinates the activities of the divisions, the corporate functions and the global business service organization. The Executive Committee is also responsible for leadership development.

Members of the Executive Committee

Name	Nationality	Year of Birth	Function
Pierre-Alain Ruffieux	Swiss	1969	Chief Executive Officer
Rodolfo J. Savitzky	Swiss / Mexican	1962	Chief Financial Officer (until November 2021)
Philippe Deecke	Swiss / German / French	1972	Chief Financial Officer (since December 2021)
Caroline Barth	British	1972	Chief Human Resources Officer
Stefan Stoffel	Swiss	1966	Head, Group Operations
Claude Dartiguelongue	French	1959	President, Capsules & Health Ingredients
Gordon Bates	British	1965	President, Small Molecules
Jean-Christophe Hyvert	Swiss	1972	President, Biologics and Cell & Gene

Limitation of Number of Mandates

According to Article 26 of the [Lonza Articles of Association](#), no member of the Executive Committee may hold more than:

- One additional mandate in a listed company
- Two additional mandates in non-listed companies
- Ten mandates in associations, charitable foundations, trusts and employee welfare foundations.

Mandates are mandates in the supreme governing body of a legal entity that is required to be registered in the commercial register or a comparable foreign register. Mandates in different legal entities that are under joint control or in the same beneficial ownership are deemed to be a single mandate. Mandates in companies that are controlled by Lonza or that control Lonza are not subject to the limitation set forth above; no member of the Executive Committee may hold more than five mandates at the request of Lonza or companies controlled by it.

Management Contracts

Lonza Group Ltd has not entered into management contracts with companies or natural persons not belonging to the Group.

CVs Executive Committee

Members of the Executive Committee as of 31 December 2021



Pierre-Alain Ruffieux, PhD

Nationality: Swiss
Year of birth: 1969

Chief Executive Officer (CEO) and Member of the Executive Committee (since November 2020).

Pierre-Alain Ruffieux holds a doctorate in Biotechnology and a master's degree in Chemical Engineering and Biotechnology from the Swiss Federal Institute of Technology (EPFL), Lausanne (CH).

Former Activities and Functions

- Head of Global Pharma Technical Operations & Member Pharma Executive Team, F. Hoffmann-La Roche (2017–2020)
- Head of Quality and Compliance, Global Pharma Technical Operations, F. Hoffmann-La Roche (2015–2017)
- Head of Quality, Pharmaceutical Division & Member Pharmaceutical Executive Committee, Novartis Pharmaceuticals (2012–2015)
- Head of Global Pharma Technical Operations & Biologics Quality Assurance, Novartis Pharmaceuticals (2010–2012)
- Global Head of Quality for Biopharmaceutical, Novartis Pharmaceuticals (2009–2010)
- Various positions in technical development and manufacturing at Novartis Pharmaceuticals & Sandoz, Novartis Group (2003–2009)
- Various positions in technical development and manufacturing at Serono (now Merck Serono) (1998–2003)



Philippe Deecke

Nationality: Swiss / German / French
Year of birth: 1972

Chief Financial Officer (CFO) and Member of the Executive Committee (since December 2021).

Philippe Deecke holds a Master's Degree in Industrial Management and Manufacturing from ETH Zurich (CH) and an MBA from Cornell University Johnson School (US).

Former Activities and Functions

- Chief Financial Officer, Novartis Oncology (2021)
- Chief Financial Officer, Sandoz, division of Novartis (2017–2021)
- Chief Financial Officer, Alcon EMEA, division of Novartis (2015–2021)
- Head Group Business Planning and Analysis, Novartis International AG (2012–2015)
- Chief Financial and Administration Officer, Novartis Schweiz AG (2010–2012)
- Project Director, Novartis International AG (2008–2010)
- Head Finance, Novartis Pharmaceutical Inc. (US) (2006–2008)
- Assistant to CEO, Novartis International AG (2005–2006)
- Associate Principal, McKinsey & Company (1998–2005)



Caroline Barth

Nationality: British
Year of birth: 1972

Chief Human Resources Officer (CHRO) and Member of the Executive Committee (since April 2020).

Caroline Barth holds a degree in European Business Studies from the University of Sunderland (UK) and an MBA from The Open University (BE).

Former Activities and Functions

- Global Head of Human Resources, Pharma, Novartis Pharma AG (2016–2020)
- Global Head Pharma Strategy, Novartis Pharma AG (2019)
- Global Head of Human Resources, Pharma Manufacturing and Quality, Novartis Pharma AG (2014–2016)
- Global Head of Human Resources, Central & Eastern Europe, Novartis Pharma AG (2013–2014)
- VP, Human Resources Canada Pharma & Corporate HR Leader, Novartis Pharma AG (2010–2013)
- Head of Talent Management, Organizational Development & Staffing, Europe, Novartis Pharma AG (2008–2010)
- Head of Human Resources Global IT, Novartis Pharma AG (2006–2008)
- Human Resources Integration Leader, Novartis Pharma AG (2004–2006)
- HR Communications Leader, EMEA & APAC, Cisco Systems (2001–2003)
- HR Generalist, Emerging Markets, Cisco Systems (1997–2001)



Stefan Stoffel

Nationality: Swiss
Year of birth: 1966

Head, Group Operations and Member of the Executive Committee (since March 2019).

Stefan Stoffel holds a Bachelor's degree in engineering from Lucerne University of Applied Sciences and Arts (CH).

Former Activities and Functions

- Head of Lonza Pharma & Biotech Strategic Growth Investments and Ibex® Solutions (2016–2019)
- Head of Lonza Pharma & Biotech Operations (2013–2016)
- General Manager of Lonza Chemical Operations Business Unit (2010–2013)
- Head of Lonza's Small Molecules Exclusive Synthesis Business Unit (2009–2010)
- Head of Operations for Lonza's Small Molecules Exclusive Synthesis Business Unit (2007–2009)
- Various positions at Lonza in Engineering & Maintenance, Technical Management, Production and Operations Management for Lonza AG and Lonza Inc. (1991–2007)



Claude Dartiguelongue

Nationality: French
Year of birth: 1959

President, Capsules & Health Ingredients Division (since January 2020) and Member of the Executive Committee (since April 2021).

Claude Dartiguelongue holds a master's degree in Medical Management from the École Supérieure de Commerce de Paris, ESCP (FR), as well as in Biotechnology from the University of Grenoble (FR).

Former Activities and Functions

- President, Microbiology, Thermo Fisher Scientific (2016 – 2019)
- President, BioSciences, Becton, Dickinson and Company (BD) (2013 – 2016)
- President, Pharmaceutical Systems, BD (2009 – 2012)
- Regional and global leadership positions (primarily in Sales and Marketing), BD (2002 – 2009)



Gordon Bates

Nationality: British
Year of birth: 1965

President, Small Molecules Division (since January 2021) and Member of the Executive Committee (since April 2021)

Gordon Bates holds a master's degree in Engineering Business Management from the University of Warwick (UK).

Former Activities and Functions

- President, Lonza Chemical Division (2018 – 2020)
- Senior Vice President, Business Unit Head, Lonza Chemical and Microbial Manufacturing (2015 – 2017)
- Global Head of Sales, Lonza Pharma Custom Manufacturing (2013 – 2015)
- Head of Operations and Site Manager, Lonza Slough (UK) (2007 – 2013)
- Global Head of Lonza Operational Excellence (2003 – 2007)

Former Members of the Executive Committee in 2021¹



Jean-Christophe Hyvert

Nationality: Swiss
Year of birth: 1972

President, Biologics and Cell & Gene Divisions (since January 2021) and Member of the Executive Committee (since April 2021)

Jean-Christophe Hyvert holds a master's degree in Physics from INSA, Rennes (FR) and an MBA from the Northwestern University (USA).

Former Activities and Functions

- Chief Commercial Officer, Lonza Pharma Biotech & Nutrition Segment (2019–2020)
- Vice President, Finance, Lonza Pharma & Biotech Segment (2017–2019)
- Finance Director ECEMEA, Baxter International (2016–2017)
- Senior Director EMEA Business Development, Baxter International (2015–2016)
- Finance Director, Baxter International (2013–2014)
- Various leadership positions in Finance and Operations at Newell Rubbermaid, Lehman Brothers and Legris (covering Corporate Development, M&A and Supply Chain) (1995–2013)



Rodolfo J. Savitzky

Nationality: Swiss / Mexican
Year of birth: 1962

Chief Financial Officer (CFO) and Member of the Executive Committee (October 2016 until 30 November 2021).

Rodolfo J. Savitzky holds a degree in Industrial and Systems Engineering from the Tecnológico de Monterrey (MX) and an MBA in Finance and Economics from the University of Chicago (USA).

Former Activities and Functions

- Vice-President Controller, Lonza Pharma & Biotech Segment (2015–2016)
- Division CFO, Novartis Animal Health (2011–2015)
- Business Unit Head of Finance, Novartis Animal Health (2006–2011)
- Head of Strategic Planning and Analysis, Novartis Pharmaceuticals (2004–2005)
- Head of Business Planning and Analysis, Novartis Pharmaceuticals (2003–2004)
- Head of Finance Ophthalmics, Novartis Pharmaceuticals (2002–2003)
- Various positions at Procter & Gamble (1990–2001)

¹ Information tracked until the end of the term of employment with Lonza



Compensation, Shareholdings and Loans

Details of Board and Executive Committee compensation are contained in the Remuneration Report, respectively on [page 196](#) and [191](#).

Shareholders' Participation Rights

Voting-Rights Restrictions and Representation

Only persons with valid entries in the share register are recognized as shareholders or usufructuaries. A shareholder may only be represented at the Annual General Meeting by a legal representative, another shareholder entitled to vote or the independent proxy. Persons who do not declare to have acquired their shares in their own name and for their own account are considered "nominees" and will only be entered with voting rights in the share register up to a maximum of 2% of the share capital, unless the entitled persons are revealed. The details are set out in Article 6 of the [Lonza Articles of Association](#). This requirement ensures compliance with applicable anti-money laundering laws, but is not meant to serve as takeover defense. This restriction may only be removed by a resolution of a Shareholders' Meeting with a quorum in accordance with Swiss law. Each share has the right to one vote and is entitled to dividend. The shares held by Lonza are not entitled to vote at the Annual General Meeting and bear no dividend. Lonza may use an electronic voting system for all the resolutions to be taken at its Annual General Meeting. The [Lonza Articles of Association](#) do not contain any other rules on electronic participation in the Shareholders' Meeting, nor specific rules on the issue of instructions to the independent proxy.

Statutory Quora

Except as otherwise stipulated by law, an absolute majority of the votes represented at the Annual General Meeting is required for resolutions and elections. For certain important matters such as a change of the company purpose and domicile, the dissolution of the company without liquidation, and certain matters relating to capital changes, Article 704 of the Swiss Code of Obligations requires at least two-thirds of the voting rights represented and an absolute majority of the nominal value of shares represented.

Convocation of Shareholders' Meetings

Ordinary Shareholders' Meetings are called in accordance with the law and the [Lonza Articles of Association](#). Extraordinary Shareholders' Meetings must be called upon resolution of a Shareholders' Meeting or if demanded by one or more shareholders representing at least 5% of the share capital. Lonza posts the invitation to shareholders at least 20 days before the Annual General Meeting and publishes it on its website, as well as in the Swiss Official Gazette of Commerce.

Agenda

One or more shareholders representing together shares with a par value of CHF 100,000 may request an item to be included in the agenda of a Shareholders' Meeting. The request to include an item must be submitted in writing at least 40 days before the meeting, stating the item to be included and the motions.

Entry in the Share Register

Purchasers of Lonza shares may submit a request to be entered, without limitation, as shareholders with voting rights in the share register, provided they expressly declare that they have acquired these shares in their own name and on their own account. Special rules exist for persons who do not expressly declare in the entry application that they hold the shares on their own account (nominees) – see Limitations on Transferability and Nominee Registrations, [page 205](#). There are no special rules in the [Lonza Articles of Association](#) concerning a deadline for entry in the share register. The share register will be closed this year on 21 April 2022 at 5:00 pm CEST.

Changes of Control and Defense Measures

Duty to Make an Offer

According to the Swiss Federal Act on Financial Infrastructures and Market Conduct in Securities and Derivatives Trading (Financial Market Infrastructure Act, FMIA), an investor who acquires more than 33⅓% of all voting rights (directly, indirectly or in concert with third parties) whether they are exercisable or not, is required to submit a takeover offer for all shares outstanding. No special opting-out or opting-up dispositions are contained in the [Lonza Articles of Association](#).

Clauses on Change of Control

The employment agreements of the Executive Committee members contain certain clauses on change of control, which are outlined in the Compensation of the Executive Committee section of the Remuneration Report. In addition, Lonza's Long-Term Incentive Plan (LTIP) provides that unvested awards or blocked shares unconditionally vest upon change of control (see Compensation of the Executive Committee section of the Remuneration Report, [page 191](#)).

Auditors

Duration of the Mandate and Term of Office of the Auditor in Charge

The independent auditor, KPMG AG, Raffelstrasse 28, 8045 Zurich, Switzerland, has held the mandate as the external statutory auditor of Lonza Group Ltd and the Group since 1999. The external statutory auditor is elected at the Annual General Meeting for a term of one year. The criteria for selection of external auditors include independence, quality, reputation and cost of services.

Florin Krapp from KPMG AG has been nominated as new lead auditor in charge for the financial year 2021. Lonza's Audit and Compliance Committee, together with KPMG AG ensure that the auditor in charge is rotated at least every seven years.

The Board of Directors proposes that KPMG AG be re-elected as auditor for the 2022 business year.

Auditing Fees and Additional Fees

The fees for professional services paid to KPMG AG for the years under audit ended 31 December 2021 and 2020 are as follows:

Million CHF	2021	2020
Audit services	4.179	4.833
Audit-related services		
- Assurance – transaction related	0.865	3.401
- Assurance – other	0.000	1.027
Tax services	0.008	0.133
Other services	1.483	3.873
Total	6.635	13.266

Audit services are provided as required by law and include the audit of the consolidated financial statement of Lonza Group Ltd as well as the required statutory audits of Lonza Group entities.

Audit-related services include other assurance and accounting services provided by the independent auditors but which may not exclusively be provided by the statutory auditor. These services go beyond the legal requirements and may include, inter alia, other attestation services, comfort letters, audits in connection with non-recurring transactions, consents and consultations, as well as

audit services related to the performance of historical carve-out audits of the Specialty Ingredients business. Tax services represent tax compliance, assistance with historical tax matters, and other related services. Other services in 2021 and 2020 primarily related to vendor due diligence procedures and reporting for which an independent report was to be issued related to the divestment of the Specialty Ingredients business and further provision of accounting and reporting guidance, as well as, training in finance and relevant regulations.

Supervisory and Control Instruments vis-à-vis the Auditors

The Audit and Compliance Committee is responsible for evaluating the performance and independence of the external auditors on behalf of the Board of Directors. This evaluation occurs at least once a year. The criteria applied for the assessment include professional competence, sufficiency of resources, the ability to provide effective and practical recommendations and coordination of the external auditors with the Audit and Compliance Committee and senior management. In the reporting year, KPMG AG attended five Audit and Compliance Committee

meetings. In those meetings, the external auditors presented the 2021 audit strategy and their 2021 results.

The Comprehensive Auditor's Report to the Board of Directors prepared by KPMG AG summarizes the reports presented to the Audit and Compliance Committee throughout the year. Within the annual approved budget, there is an amount permissible for non-audit services that the external auditors may perform. Within the scope of the approved and budgeted amount, the Chief Financial Officer can delegate non-audit-related mandates to the external auditors, subject to all applicable auditor independence regulations.

The Board of Directors has determined the rotation interval for the auditor in charge to be at least every seven years, as defined by the Swiss Code of Obligations.

The Audit and Compliance Committee reviews Lonza's financial reporting process on behalf of the Board of Directors. Lonza's management is responsible for preparing the financial statements and the reporting process, including the system of internal controls. The Audit and Compliance Committee is also responsible for overseeing the conduct of the activities by Lonza management and the external auditors.

The external auditor, KPMG AG, is responsible for expressing an opinion on the accounting records and the financial statements prepared in accordance with Swiss law and the [Lonza Articles of Association](#). KPMG AG is also responsible for expressing an opinion on the consolidated financial statements (balance sheet, income statement, statement of comprehensive income, cash flow statement, statement of changes in equity and notes) prepared in accordance with the International Financial Reporting Standards (IFRS), which is issued by the International Accounting Standards Board (IASB), and with Swiss law. KPMG AG also audited the Lonza Remuneration Report 2021 with respect to the information required by Articles 14 to 16 of the Swiss Ordinance Against Excessive Compensation in Stock-Exchange-Listed Companies.

Information Policy and Key Reporting Dates

Lonza pursues a proactive and professional communication policy. Lonza publishes price-sensitive information in accordance with the obligation to disclose price-sensitive facts as required by the SIX Swiss Exchange. Ad hoc notices are made available on Lonza's [news site](#). Additionally, Lonza's website provides a [news and subscription service](#) that allows interested parties to receive, via e-mail distribution, free and timely notification of price-sensitive facts.

Corporate Communications and Investor Relations report directly to the Chief Executive Officer. On basic matters of general corporate policy, Corporate Communications and Investor Relations receive their directives from the Executive Committee. Lonza makes the Annual Report, the Half-Year Results and Full-Year Results available to all interested parties as a [PDF download](#).

The invitation to the Annual General Meeting is published on our [website](#) and in the Swiss Official Gazette of Commerce. It is also sent by mail to the shareholders entered in the share register. Our website is regularly updated and provides relevant information such as share-price development, news releases and presentations. Financial results conference calls were held and a Capital Markets Day (CMD) meeting in 2021 took place in Zurich and by conference call. Lonza manages an annual program of investor meetings. To the extent possible under COVID regulations, shareholders, potential investors and financial analysts are also welcomed at our headquarters in Basel, Switzerland.

Anticipated Key Reporting Dates

The list of all corporate events of special interest is subject to change during the year as dates are adjusted and added. Updated information is found on the [Investor Relations page](#) of our website or on [page 21](#) of the Annual Report.

Black-out Periods and Trading Bans

Lonza has two regular black-out periods which start on (i) June 9 and (iv) December 10 every year and end on the day after the public announcement of the company's Half-Year and Full-Year Results, respectively. During these black-out periods, members of the Board of Directors and Executive Committee as well as several employees (which are deemed to potentially have access to sensitive information during these periods) are not allowed to trade Lonza securities.

In addition, Lonza may issue a special trading ban outside of the black-out periods for persons which potentially have access to sensitive information (in case of specific events or projects, ad-hoc announcements, profit warnings, etc.). Such special trading ban is upheld as long as the potentially sensitive information has not been made public. The persons in scope are informed of the start and the end of such special trading ban and are not allowed to trade Lonza securities during such period.

Legal Disclaimer

Forward-Looking Statements

Forward-looking statements contained herein are qualified in their entirety as there are certain factors that could cause results to differ materially from those anticipated. Any statements contained herein that are not statements of historical fact (including statements containing the words “outlook,” “guidance,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should be considered to be forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainty.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the timing and strength of new product offerings; pricing strategies of competitors; the company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; difficulty to maintain relationships with employees, customers and other business partners; and changes in the political, social and regulatory framework in which the company operates, or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis.

In particular, the assumptions underlying the Outlook 2022 and Mid-Term Guidance 2024 herein may not prove to be correct. The statements in the section on Outlook 2022 and Mid-Term Guidance 2024 constitute forward-looking statements and are not guarantees of future financial performance.

Lonza’s actual results of operations could deviate materially from those set forth in the section on Outlook 2022 and Mid-Term Guidance 2024 as a result of the factors described above or other factors. Investors should not place undue reliance on the statements in the section on Outlook 2022 and Mid-Term Guidance 2024. Except as otherwise required by law, Lonza disclaims any intention or obligation to update any forward looking statements as a result of developments occurring after this presentation was published.

No Warranty and No Liability

While Lonza Group Ltd and its affiliates (collectively and individually, the “Lonza Group”) make efforts to include accurate and up-to-date information, they make no representations or warranties, express or implied, as to the accuracy or completeness of the information provided on this site and disclaim any liability for the use of this site or any site linked to it. Lonza Group may change this site at any time without notice but does not assume any responsibility to update it. Lonza Group makes no warranties, express or implied, and assumes no liability in connection with any use of this publication. Every user agrees that all access and use of this site and of any site linked to from this site and the information contained herein and therein are at their own risk. Neither Lonza Group (including its agents, directors, and employees) nor any other party involved in creating this site is liable for any direct, incidental, special, consequential, indirect or punitive damages or other damages arising out of your access to or use of this site, including but not limited to viruses or malware that may infect your computer equipment or software and any damages for lost profits, business interruption, loss of programs or other data on your information handling system or otherwise, even if Lonza Group or any other person or entity is advised of the possibility of such damages and irrespective of whether such damages arise in an action of contract, negligence or other tortious or legal action.

No Offer and No Solicitation

The information provided in the report does not constitute an offer of or solicitation for the purchase or disposal of, trading or any transaction in any Lonza Group securities. Investors must not rely on this information for investment decisions.

Limited Use

Lonza Group hereby grants you the right to display, store and reproduce copies of this publication for personal use subject to the following conditions:

1. The publication may be used for internal purposes only and may not be sold or distributed for commercial or political purposes;
2. The publication may not be modified, diffused, reposted or transmitted in any respect;
3. The copyright notice must appear on every copy of the work or portion thereof.

Trademarks

The trademarks, logos and service marks (collectively, the “Trademarks”) used or mentioned on this publication are registered and unregistered trademarks of Lonza Group Ltd, one of its affiliates or third parties and are legally protected in Switzerland and/or USA or European Union. Be aware that certain product names are trademarks, even if not specifically mentioned.

Nothing on this publication should be construed as granting, by implication, estoppel or otherwise, any license or right in or to the Trademarks without the express prior written permission of Lonza Group Ltd or such other third party. Your misuse of the Trademarks on this publication and in its conditions is strictly prohibited.

Product Use and Recommendations

This report has been designed to provide general information about Lonza Group and its products. This report is not intended to provide any instruction on the appropriate use of products produced and supplied by Lonza Group. All recommendations for handling, storage or use of products, whether given in writing, orally, or to be implied from the results of tests are based on the state of Lonza Group’s knowledge at the time such recommendations are made. Notwithstanding any such recommendations, you as the user of such products must make your own determination and satisfy yourself that the products supplied by Lonza Group and the information and recommendations given by Lonza Group are (i) suitable for intended process or purpose, (ii) are in compliance with environmental, health and safety regulations, and other regulations in the regions and countries where they are purchased, offered for sale, marketed, sold, and used and (iii) will not infringe any third party’s intellectual property rights.

Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

For publications and further information, please contact:

Lonza Group Ltd

Muenchensteinerstrasse 38
4002 Basel, Switzerland
Tel +41 61 316 81 11
www.lonza.com

Investor Relations

Tel +41 61 316 8540
investor.relations@lonza.com

Media / Corporate Communications

Tel +41 61 316 2283
media@lonza.com

Share Register

c/o Computershare Schweiz AG
P.O. Box 4601 Olten, Switzerland
Tel +41 62 205 77 00
Fax +41 62 205 77 90
share.register@computershare.ch

Production Details:

Corporate Communications, Lonza Group Ltd, Basel (CH)
Design and Illustration: SevenThree Creative, Edinburgh (UK)
and Lonza Design Team
Lonza Online Annual Report: Sears Davies Ltd, London (UK)
Pictures: iStock, Getty Images, Lonza
Board of Directors, Executive Committee Members and Leadership
Portraits: Julian Salinas, Matthew Lee and Lonza

The 2021 Annual Report PDF version legally prevails over the 2021 Online Annual Report.

© 2022 Lonza Ltd / All rights reserved